Xerthra
Xerthra BMAC
Bone marrow aspirate concentrate
BMAC concentrates up to 8 times more mesenchymal cells and 4 times more platelets than raw bone marrow aspirate, indicated for advanced osteoarthritis (grades 3 and 4), meniscus regeneration and biological cartilage reconstruction.
Indications
- Support for knee meniscus regeneration
- Support for biological cartilage reconstruction
- Support for bone marrow edema treatment through subchondral administration
- Intra-articular injections in osteoarthritis
Xerthra separation system
- Autologous procedure
- No risk of immune response or disease transmission. Tissues are stimulated by the patient's own growth factors.
- Low aspirate volume
- Requires 3 draws of 13.5 ml of bone marrow aspirate (40.5 ml total) for the procedure.
- Short centrifugation time
- A fast protocol that preserves sterility and safety.
- Makrolon polymer
- Very low surface energy and low affinity for platelets and leukocytes, ensuring maximum recovery of these factors at the end of the protocol.
- Guaranteed stabilization
- Transverse rings ensure stability during centrifugation, preventing hemolysis.
Technology
Xerthra tube technology
Closed system with pressure equalization
Blood transfer without removing the stopper, eliminating exposure and reducing contamination risk throughout the process.
Very low surface energy
A property of the Makrolon polycarbonate that minimizes platelet and leukocyte adhesion to the tube's inner wall, resulting in greater cell recovery in the final concentrate.
Transverse stabilization rings
Internal structures that keep the blood column stable during centrifugation, preventing hemolysis and preserving the integrity of the separated fractions.
Precision volumetric markings
Allow the exact volume to be obtained at each separation stage, with strict control over the final dose to be applied.
